Table 2.
Characteristics of patient-reported fatigue as an ADR of biologics (N = 108)
| No. of patients reporting HCP contact following fatigue | 78 (72) |
| Specialist doctor | 65 (60) |
| General practitioner | 27 (25) |
| Nurse | 35 (32) |
| Other | 4 (4) |
| No. of patients who reported an HCP action | 78 (72) |
| Discontinuation | 7 (6) |
| Dose adjustment | 13 (12) |
| Treatment | 10 (9) |
| Referral | 5 (5) |
| Mentioned, no other action | 39 (36) |
| Othera | 17 (16) |
| No. of patients with a status of ‘fatigue’ in the last completed questionnaire | |
| Recovered | 28 (26) |
| Improving | 17 (16) |
| No change | 54 (50) |
| Aggravating | 9 (8) |
| No. of patients reporting fatigue and hospitalization | 3 (3) |
| No. of patients reporting self-initiated action following fatigue | 63 (58) |
| Naranjo score | |
| Doubtful | 5 (5) |
| Possible | 75 (70) |
| Probable | 28 (26) |
| Certain | 0 (0) |
| Mean ADR burden score ± SD | 2.8 ± 0.9 |
Data are expressed as n (%) unless other specified
ADR adverse drug reaction, HCP healthcare professional, SD standard deviation
aOther HCP actions: further examination, 6; adjusting concomitant therapy, 6; other therapy, 3